Allergan partners with tribe to fight IPR

In an effort to create a shield against patent challenges under the U.S. Patent and Trademark Office’s inter partes review process, Allergan plc (NYSE:AGN) announced Friday that it had transferred ownership of six patents covering dry eye drug Restasis cyclosporine to the Saint Regis Mohawk Tribe. Citing its sovereign immunity as a recognized tribal government, the tribe is filing a motion to dismiss ongoing IPR challenges to the patents, Allergan reported.

Allergan said

Read the full 727 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE